Abstract: The present invention provides a process for the recombinant DNA production of a mature form of the PRRSV ORF 3 or ORF 4 protein. This is achieved by the co-expression of the PRRSV ORF 2, ORF 3 and ORF 4 proteins by the same cell.
Type:
Grant
Filed:
March 14, 1996
Date of Patent:
January 12, 1999
Assignee:
Akzo Nobel, N.V.
Inventors:
Petrus Alphonsus Maria Van Woensel, Karl-Klaus Conzelmann
Abstract: The invention relates to a steroid derivative which steroidal skeleton is bound at carbon atom 17 to a spiromethylene ring of the formula: ##STR1## wherein R.sub.a and R.sub.b are independently selected from the group consisting of hydrogen, methyl, and halogen; m is 1 or 2; and the asterisk denotes carbon atom 2 of the spiromethylene ring which is carbon atom 17 (or carbon atom 17.alpha. of a homosteroid skeleton) of the steroid. The steroids have progestational or antiprogestational activity.
Type:
Grant
Filed:
November 3, 1997
Date of Patent:
December 29, 1998
Assignee:
Akzo Nobel N.V.
Inventors:
Johannes Antonius Maria Hamersma, Everardus Otto Maria Orlemans, Johannes Bernardus Maria Rewinkel
Abstract: The invention relates to peptides or fragments thereof which are immunochemically reactive with Epstein-Barr Virus (EBV) antibodies. New antibodies directed to said peptides or fragments thereof are also part of the invention.The invention also relates to a method for the detection of EBV or antibodies directed against EBV in a test fluid and also to an immunochemical reagent comprising a peptide, a fragment or a polypeptide according to the invention and a test kit to be used when applying the said detection methods.Detection of EBV in a test fluid or tissue specimen using antibodies, monoclonal and polyclonal, directed to the said peptide, which have the characteristics of detecting both native and denatured EBV-EA protein is also part of said invention.
Abstract: A vaccine and a method of raising neutralizing antibodies against HIV infection. The vaccine comprises a complex of gp120 covalently bonded to CD4 or to succinyl concanvalin A. Also disclosed are immunological tests using the complex or antibody thereto for detection of HIV infection.
Type:
Grant
Filed:
December 20, 1995
Date of Patent:
December 1, 1998
Assignee:
Akzo Nobel N.V.
Inventors:
Anthony L. Devico, Ranajit Pal, Mangalasseril G. Sarngadharan
Abstract: The present invention relates to novel peptides derived from the autoantigen HC gp-39, said peptides comprising at least one of the amino acid sequences FGRSFTILAS (SEQ ID No. 1), FTLASSETG (SEQ ID No. 2), YDDQESVKS (SEQ ID No. 3) and FSKIASNTQ (SEQ ID No. 4). The peptides resemble MHC Class II restricted T-cell epitopes present on the autoantigen HC gp-39 in articular cartilage. HC gp-39, proteins comprising an amino acid sequence which exhibits at least 50% homology with the amino acid sequence YKLVCYYTSWSQYREGDGSCFPDALDRFLCTHIIYSFANISND (SEQ ID No: 10) and said peptides can be used in antigen-specific treatment of articular cartilage destruction in autoimmune diseases in mammals to induce systemic tolerance of the immune system. The autoantigen HC gp-39, proteins comprising an amino acid sequence which exhibits at least 50% homology with the amino acid sequence YKLVCYYTSWSQYREGDGSCFPDALDRFLCTHIIYSFANISND (SEQ ID NO: 10) and said peptides are also suitable to induce arthritis in animals, preferably mice.
Type:
Grant
Filed:
April 18, 1996
Date of Patent:
December 1, 1998
Assignee:
Akzo Nobel N.V.
Inventors:
Anna Maria Helena Boots, Gijsbertus Franciscus Maria Verheijden, Ebo Sybren Bos
Abstract: This invention relates to novel Eimeria proteins with immunogenic properties as well as to DNA sequences encoding these proteins. These proteins can be administered to poultry thereby protecting the birds against coccidiosis. In addition the DNA encoding these proteins can be used for the preparation of a vector vaccine against coccidiosis.
Type:
Grant
Filed:
June 21, 1996
Date of Patent:
December 1, 1998
Assignee:
Akzo Nobel N.V.
Inventors:
Janene Marilyn Bumstead, Paul Patrick James Dunn, Fiona Margaret Tomley, Arnoldus Nicolaas Vermeulen
Abstract: The present invention is related to an improved method for the quantification of nucleic acid, which can be performed with a minimal amount of nucleic acid amplification reactions. The method according to the invention for the quantification of analyte nucleic acid in a sample comprises the steps of: adding to the sample different respective amounts of different nucleic acid constructs, each construct being distinguishable from the analyte nucleic acid and capable of being co-amplified with the analyte nucleic acid; subjecting the sample to a nucleic acid amplification procedure, using amplification reagents capable of reacting with both the analyte nucleic acid and the nucleic acid constructs; detecting the relative amounts of amplificates derived from analyte nucleic acid and each nucleic acid construct; calculating the amount of analyte nucleic acid from said relative amounts.
Type:
Grant
Filed:
September 26, 1997
Date of Patent:
November 17, 1998
Assignee:
Akzo Nobel N.V.
Inventors:
Thomas Augustinue Maria Beumer, Marinus Gerardus Johannes van Beuningen, Tim Kievits
Abstract: Disclosed is a method of quantifying a target nucleic acid in a test sample by adding to the test sample a known number of molecules of a corresponding nucleic acid comprising a well-defined mutant sequence. Said mutant sequence being discriminatory from the target nucleic acid. Subsequently a competitive amplification reaction of the nucleic acid is performed after which quantification of the amplified nucleic acid is performed by a differential detection.
Type:
Grant
Filed:
February 7, 1995
Date of Patent:
November 10, 1998
Assignee:
Akzo Nobel N.V.
Inventors:
Bob van Gemen, Tim Kievits, Peter F. Lens
Abstract: The present invention is directed to diagnostic reagents for the detection of antibodies against the Epstein Barr Virus and a method for the detection of antibodies to the Epstein Barr Virus in a sample.The diagnostic reagents according to the invention comprise a combination of at least part of an Epstein Barr viral structural protein, preferably a Epstein Barr VCA-protein or an Epstein Barr MA protein, and at least part of an Epstein Barr EBNA protein. Preferably, the VCA-protein is VCA-p18 protein, the MA-protein is MA-gp350/220 protein and the EBNA-protein is EBNA-1 protein.It has been found that the combination of a VCA-protein or a MA-protein, and an EBNA protein, into a single diagnostic assay yields an EBV-antibody detection method with greater sensitivity and accuracy than current methods.
Type:
Grant
Filed:
September 14, 1994
Date of Patent:
October 27, 1998
Assignee:
Akzo Nobel N.V.
Inventors:
Jaap Michiel Middeldorp, Wouterus Marinus Johannes van Grunsven
Abstract: The invention is concerned with a protein having the immunological properties of Eimeria tenella which is reactive with a monoclonal antibody E. TEN 11P-2 raised against E. tenella sporozoites.The invention also relates to polypeptide fragments of this protein which can be used for immunization against E. tenella. These proteins and polypeptides can be prepared by isolation from E. tenella, by chemical synthesis or by recombinant DNA methods using the polynucleotides described herein or related sequences.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
September 29, 1998
Assignee:
Akzo Nobel N.V.
Inventors:
Lorraine Elizabeth Clarke, Fiona Margaret Tomley, Rein Dijkema, Arno Vermeulen
Abstract: The present invention is concerned with a hog cholera virus vaccine comprising a polypeptide characteristic of hog cholera virus. Vector vaccines capable to express a nucleic acid sequence encoding such a polypeptide also form part of the present invention. Said polypeptide and nucleic acid sequence can also be used for the detection of hog cholera virus infection.
Type:
Grant
Filed:
June 12, 1997
Date of Patent:
September 22, 1998
Assignee:
Akzo Nobel N.V.
Inventors:
Gregor Meyers, Tillmann Rumenapf, Heinz-Jurgen Thiel
Abstract: A method for in-vivo targeting a functional moiety in a patient by administering a targeting moiety coupled to an affinity component, wherein the targeting moiety has affinity for binding sites in a target area, and administering a binding partner to the affinity component coupled to a functional moiety to localize the functional moiety in the target area. Preferably the targeting moiety is an antibody and the functional moiety is a radiometal when performing in vivo imaging or therapy. The affinity component may be a novel methotrexate analog.
Type:
Grant
Filed:
May 30, 1995
Date of Patent:
September 15, 1998
Assignee:
Akzo Nobel N.V.
Inventors:
Nicholas Pomato, Richard P. McCabe, Gregory Alan Hawkins, Reinhard Bredehorst, Chong-Ho Kim, Carl-Wilhelm Ernst Vogel
Abstract: The invention relates to a vaccine comprising an antigenic substance and a mixture of two adjuvants wherein one adjuvant is oil-based whereas the other adjuvant is water-based.
Type:
Grant
Filed:
July 22, 1996
Date of Patent:
September 8, 1998
Assignee:
Akzo Nobel N. V.
Inventors:
Per Martin Aasjord, Audun Helge Nerland, Dag Harald Knappskog
Abstract: This invention relates to novel Eimeria proteins with immunogenic properties as well as to DNA sequences encoding these proteins. These proteins can be administered to poultry thereby protecting the birds against coccidiosis. In addition the DNA encoding these proteins can be used for the preparation of a vector vaccine against coccidiosis.
Type:
Grant
Filed:
November 10, 1994
Date of Patent:
August 18, 1998
Assignee:
Akzo Nobel N.V.
Inventors:
Janene Marilyn Bumstead, Paul Patrick James Dunn, Fiona Margaret Tomley, Arnoldus Nicolaas Vermeulen
Abstract: The invention is concerned with novel Eimeria proteins with immunogenic properties as well as with DNA sequences encoding these proteins. These proteins can be administered to chickens thereby protecting the chickens against coccidiosis. In addition the DNA encoding these proteins can be used for the preparation of a vector vaccine against coccidiosis.
Type:
Grant
Filed:
June 6, 1995
Date of Patent:
August 11, 1998
Assignee:
Akzo Nobel N.V.
Inventors:
Arnoldus Nicolaas Vermeulen, Paul van den Boogaart, Jacobus Johannus Kok
Abstract: The present invention relates to a vaccine against a virus associated with antibody-dependent-enhancement of viral infectivity. Such a vaccine comprises a herpesvirus vector which is able to spread from cell-to-cell and which does produce non-infectious progeny virions having a gene encoding an antigen of said virus inserted into the herpesvirus genome.
Type:
Grant
Filed:
December 20, 1994
Date of Patent:
August 4, 1998
Assignee:
Akzo Nobel N.V.
Inventors:
Nicolaas Visser, Petrus Alphonsus Maria van Woensel, Thomas Christoph Mettenleiter
Abstract: The invention is concerned with novel Eimeria proteins with immunogenic properties as well as with DNA sequences encoding these proteins. These proteins can be administered to chickens thereby protecting the chickens against coccidiosis. In addition the DNA encoding these proteins can be used for the preparation of a vector vaccine against coccidiosis.
Type:
Grant
Filed:
September 21, 1994
Date of Patent:
August 4, 1998
Assignee:
Akzo Nobel N.V.
Inventors:
Arnoldus Nicolaas Vermeulen, Paul van den Boogaart, Jacobus Johannus Kok
Abstract: The present invention relates to peptides immunoreactive with anti-apolipoprotein(a) antibodies and to their use in raising monoclonal and polyclonal antibodies, in immunoassays and of their corresponding oligonucleotides as probes and primers in nucleic acid methodology.
Abstract: The present invention is concerned with a polypeptide of Eimeria which can be used for the immunization of poultry against coccidiosis. Furthermore, the invention comprises a DNA fragment of Eimeria coding for said polypeptide.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
July 21, 1998
Assignee:
Akzo Nobel N.V.
Inventors:
Arno Vermeulen, Rein Dijkema, Jacobus Johannes Kok
Abstract: The present invention is concerned with a Feline herpesvirus (FHV) mutant comprising a heterologous gene introduced into an insertion-region of the FHV genome.The invention also relates to a vector vaccine comprising such an FHV mutant which expresses a heterologous polypeptide derived from a feline pathogen and induces an adequate immune response in an inoculated host against both FHV and the feline pathogen.
Type:
Grant
Filed:
July 17, 1996
Date of Patent:
July 21, 1998
Assignee:
Akzo Nobel N.V.
Inventors:
Martha Jacoba Willemse, Paulus Jacobus Antonius Sondermeijer